Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, 3-arm, Parallel Group, Placebo- and Positive-controlled Study to Investigate the Effects of Setmelanotide on QTc Interval in Healthy Subjects
Conditions
Interventions
Setmelanotide
Moxifloxacin
+2 more
Locations
1
United States
Parexel Early Phase Clinical Unit (Los Angeles)
Glendale, California, United States
Start Date
August 5, 2021
Primary Completion Date
April 7, 2022
Completion Date
April 7, 2022
Last Updated
May 3, 2024
NCT00090662
NCT06290258
NCT06716502
NCT07310264
NCT07483606
NCT07310901
Lead Sponsor
Rhythm Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions